Wedge Capital Management L L P NC lowered its stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 14.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,943 shares of the medical instruments supplier’s stock after selling 25,011 shares during the period. Wedge Capital Management L L P NC’s holdings in Harvard Bioscience were worth $756,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of HBIO. BlackRock Inc. boosted its holdings in Harvard Bioscience by 105.3% during the second quarter. BlackRock Inc. now owns 2,934,267 shares of the medical instruments supplier’s stock worth $15,699,000 after buying an additional 1,504,668 shares during the last quarter. First Light Asset Management LLC boosted its holdings in Harvard Bioscience by 9.4% during the second quarter. First Light Asset Management LLC now owns 5,951,014 shares of the medical instruments supplier’s stock worth $31,838,000 after buying an additional 509,724 shares during the last quarter. Northern Trust Corp boosted its holdings in Harvard Bioscience by 339.6% during the second quarter. Northern Trust Corp now owns 391,154 shares of the medical instruments supplier’s stock worth $2,093,000 after buying an additional 302,184 shares during the last quarter. Royce & Associates LP boosted its holdings in Harvard Bioscience by 20.9% during the second quarter. Royce & Associates LP now owns 1,565,000 shares of the medical instruments supplier’s stock worth $8,373,000 after buying an additional 270,306 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Harvard Bioscience by 951.3% during the first quarter. Millennium Management LLC now owns 225,619 shares of the medical instruments supplier’s stock worth $1,128,000 after purchasing an additional 204,158 shares during the period. Hedge funds and other institutional investors own 73.03% of the company’s stock.

In other news, CFO Robert E. Gagnon sold 8,889 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $5.77, for a total transaction of $51,289.53. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 7.60% of the company’s stock.

A number of equities research analysts have recently commented on the company. Zacks Investment Research lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. ValuEngine lowered Harvard Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd.

NASDAQ HBIO opened at $4.05 on Friday. The stock has a market cap of $155.14 million, a PE ratio of 81.00 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 1.49 and a debt-to-equity ratio of 0.73. Harvard Bioscience, Inc. has a one year low of $3.00 and a one year high of $6.70.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.04 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.04. The company had revenue of $28.71 million for the quarter, compared to analyst estimates of $28.50 million. Harvard Bioscience had a positive return on equity of 5.54% and a negative net margin of 4.18%. Research analysts anticipate that Harvard Bioscience, Inc. will post 0.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/11/10/harvard-bioscience-inc-hbio-holdings-cut-by-wedge-capital-management-l-l-p-nc.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.

Read More: Why do companies issue stock splits?

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.